### UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION	) ) ) MDL NO. 1456 ) Civil Action No. 01-12257-PBS
THIS DOCUMENT RELATES TO ALL CLASS ACTIONS	) Hon. Patti B. Saris ) Chief Mag. Judge Marianne B. Bowler )

#### **DECLARATION OF ANDREW D. SCHAU**

Andrew D. Schau, declares as follows:

- 1. I am a member of Patterson, Belknap Webb & Tyler LLP, counsel for the Johnson & Johnson defendants. I make this declaration based in part on documents and records maintained by my office, and in part on information supplied to me by other defense counsel.
- 2. Plaintiffs' motion to certify a class was fully briefed as of January 21, 2005 and argued on February 10, 2005.
- 3. Attached hereto as Exhibit 1 is a table showing the dates that the documents referenced in plaintiffs' motion to supplement the record were produced or made available for inspection.
- 4. Attached hereto as Exhibit 2 is a true and correct copy of excerpts from the rough draft of the transcript of the deposition of Gary M. Owens, taken July 22, 2005.
- 5. Attached hereto as Exhibit 3 is a true and correct copy of excerpts from the transcript of the deposition of Susan Johnson, taken March 16, 2005.

I declare under penalty of perjury that the foregoing is true and correct.

Dated: August 3, 2005

/s/ Andrew D. Schau

Andrew D. Schau

#### **CERTIFICATE OF SERVICE**

I hereby certify that on August 3, 2005 I caused a true and correct copy of the Declaration of Andrew D. Schau in Support of the Track 1 Defendants' Memorandum in Opposition to Plaintiffs' Motion to Supplement the Record to be served on all counsel of record by electronic service pursuant to Case Management Order No. 2 entered by the Honorable Patti B. Saris in MDL 1456.

/s/Andrew D. Schau
Andrew D. Schau

### EXHIBIT 1

Company	Document	Production Date
AstraZeneca	AZ0021720 – 22	December 16, 2002
1100 da 1 100 da 1 1	AZ04638881, 95	June 1, 2004
And the second s	AZ0427859, 79	June 1, 2004
The state of the s	AZ0602164, 98 – 99	September 22, 2004
	AZ0692057	January 24, 2005
	PXL02780	June 2005
BMS	BMS/AWP/00393437	July 30, 2004
	BMS/AWP/480634	July 30, 2004
	BMS/AWP/480643-44	
	BMS/AWP/393437	July 30, 2004
	BMS/AWP/01233084-089	July 30, 2004
		September 13, 2004
THE PERSON WAS A SECTION AND A COMMENT OF THE PERSON OF TH	BMS/AWP/1233090	September 13, 2004
	BMS/AWP/1233114	September 13, 2004
	BMS/AWP/1233118	September 13, 2004
	BMS/AWP/1233120	September 13, 2004
	BMS/AWP/1233124	September 13, 2004
	BMS/AWP/1233134	September 13, 2004
	BMS/AWP/1233154	September 13, 2004
	BMS/AWP/1278450	September 13, 2004
	BMS/AWP/1278456	September 13, 2004
	BMS/AWP/1278484	September 13, 2004
er a tra latin til lik berkele en enn i si stresse kij ji jede je bij ka ja bij ka benese u ka koon, a so soon,	BMS/AWP/01278475	September 13, 2004
	BMS/AWP/01278505	September 13, 2004
GSK	GSK-MDL-ZN02-052866	December 12, 2002
	GSK-MDL-ZN02-052895	December 16, 2002
er e	GSK-MDL-KY01-007599	July 16, 2003
	GSK-MDL-KY01-004553	July 16, 2003
	GSK-MDL-ZN02-103561	September 12, 2003
	The second secon	
J&J Group	MDL-CEN0003485	September 26, 2003
	MDL-OBI00055451	August 5, 2004
Novartis	App. A.1	Published 2004
Schering/Warrick	SP0012555-56	December 16, 2002
	SW0648213-15	August 30, 2004
	5 17 0040213-13	(made available for inspection)

### EXHIBIT 2

# **REDACTED**

## EXHIBIT 3

## **REDACTED**